Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 232

The DOI matches its Crossref record.

Inhaled Granulocyte/Macrophage–Colony Stimulating Factor as Therapy for Pulmonary Alveolar Proteinosis

Open access
Tazawa, Ryushi, Trapnell, Bruce C., Inoue, Yoshikazu, Arai, Toru, Takada, Toshinori, Nasuhara, Yasuyuki, Hizawa, Nobuyuki, Kasahara, Yasunori, Tatsumi, Koichiro, Hojo, Masayuki, Ishii, Haruyuki, Yokoba, Masanori, Tanaka, Naohiko, Yamaguchi, Etsuro, Eda, Ryosuke, Tsuchihashi, Yoshiko, Morimoto, Konosuke, Akira, Masanori, Terada, Masaki, Otsuka, Junji, Ebina, Masahito, Kaneko, Chinatsu, Nukiwa, Toshihiro, Krischer, Jeffrey P., Akazawa, Kohei, Nakata, Koh · 2010 · American Journal of Respiratory and Critical Care Medicine

Abstract

RATIONALE: Inhaled granulocyte/macrophage-colony stimulating factor (GM-CSF) is a promising therapy for pulmonary alveolar proteinosis (PAP) but has not been adequately studied. OBJECTIVES: To evaluate safety and efficacy of inhaled GM-CSF in patients with unremitting or progressive PAP. METHODS: We conducted a national, multicenter, self-controlled, phase II trial at nine pulmonary centers throughout Japan. Patients who had lung biopsy or cytology findings diagnostic of PAP, an elevated serum GM-CSF antibody level, and a Pa(O(2)) of less than 75 mm Hg entered a 12-week observation period. Those who improved (i.e., alveolar-arterial oxygen difference [A-aDO(2)] decreased by 10 mm Hg) during observation were excluded. The rest entered sequential periods of high-dose therapy (250 microg Days 1-8, none Days 9-14; x six cycles; 12 wk); low-dose therapy (125 microg Days 1-4, none Days 5-14; x six cycles; 12 wk), and follow-up (52 wk). MEASUREMENTS AND MAIN RESULTS: Fifty patients with PAP were enrolled in the study. During observation, nine improved and two withdrew; all of these were excluded. Of 35 patients completing the high- and low-dose therapy, 24 improved, resulting in an overall response rate of 62% (24/39; intention-to-treat analysis) and reduction in A-aDO(2) of 12.3 mm Hg (95% confidence interval, 8.4-16.2; n = 35, P < 0.001). No serious adverse events occurred, and serum GM-CSF autoantibody levels were unchanged. A treatment-emergent correlation occurred between A-aDO(2) and diffusing capacity of the lung, and high-resolution CT revealed improvement of ground-glass opacity. Twenty-nine of 35 patients remained stable without further therapy for 1 year. CONCLUSIONS: Inhaled GM-CSF therapy is safe, effective, and provides a sustained therapeutic effect in autoimmune PAP. Clinical trial registered with www.controlled-trials.com/isrctn (ISRCTN18931678), www.jmacct.med.or.jp/english (JMA-IIA00013).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/rccm.200906-0978oc

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 232

Metadata

Authors
Tazawa, R., Trapnell, B. C., Inoue, Y., Arai, T., Takada, T., Nasuhara, Y., Hizawa, N., Kasahara, Y., Tatsumi, K., Hojo, M., Ishii, H., Yokoba, M., Tanaka, N., Yamaguchi, E., Eda, R., Tsuchihashi, Y., Morimoto, K., Akira, M., Terada, M., Otsuka, J., Ebina, M., Kaneko, C., Nukiwa, T., Krischer, J. P., Akazawa, K., & Nakata, K.
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2010-06-15
Volume
181
Issue
12
Pages
1345-1354
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W2094909945
Cited by
232
References
0
FWCI
9.59
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhaled Granulocyte/Macrophage–Colony Stimulating Factor as Therapy for Pulmonary Alveolar Proteinosis. https://app.cochat.ai/papers/10.1164/rccm.200906-0978oc
The paper
Tazawa, R., Trapnell, B. C., Inoue, Y., Arai, T., Takada, T., Nasuhara, Y., Hizawa, N., Kasahara, Y., Tatsumi, K., Hojo, M., Ishii, H., Yokoba, M., Tanaka, N., Yamaguchi, E., Eda, R., Tsuchihashi, Y., Morimoto, K., Akira, M., Terada, M., . . . Nakata, K. (2010). Inhaled Granulocyte/Macrophage–Colony Stimulating Factor as Therapy for Pulmonary Alveolar Proteinosis. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.200906-0978oc

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.